The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Equity Insider published a paid commentary on behalf of MindWalk Holdings Corp., arguing that the value in AI drug discovery lies in the underlying biological data layer rather than just the models. The article profiles MindWalk's 'context layer' strategy and mentions Absci (ABSI) as a peer focused on generative design and a participant in a recent industry panel.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.